29.08.2016 • NewsElaine BurridgeLanxessmembranes

Lanxess to Double German Membranes Capacity

(c) Lanxess
(c) Lanxess

Lanxess has decided to double capacity for reverse osmosis (RO) membranes at its site in Bitterfeld, Germany, in order to meet rising demand. Jean-Marc Vesselle, head of Lanxess’ Liquid Purification Technologies business unit, said the Lewabrane plant, which is operated by wholly owned subsidiary IAB Ionenaustrauscher, is currently operating at close to its limit. The additional production will go on stream in the second half of 2017, creating up to 10 new jobs.

According to Lanxess, the market for RO membrane elements is forecast to grow at an above-average rate of 10% per year to 2020. The company added that it continuously researches all areas of modern water treatment, co-operating with the Fraunhofer Institutes for Factory Operation and Automation (IFF) in Magdeburg, and for Microstructure of Materials and Systems (IMWS) in Halle, for example.

Lanxess said it has spent €40 million on the Bitterfeld site in the last five years, growing during that time to become a leading player in the water treatment market. The Cologne-headquartered specialty chemical company also operates ion exchange resins plants in Leverkusen, Germany, and Jhagadia, India.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.